Ya-wen Hung
Taoyuan Branch
Taoyuan, TNQ, Taiwan
Taoyuan, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy.
Journal: Hepatology (Baltimore, Md.)
Published: April 09, 2025
Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning.
Journal: BMC cancer
Published: March 31, 2025
Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy.
Journal: Journal of hepatology
Published: January 04, 2024
Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma.
Journal: Liver cancer
Published: December 20, 2022
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
Journal: Journal for immunotherapy of cancer
Published: May 31, 2022
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: November 17, 2021
Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection.
Journal: Cancers
Published: July 21, 2021
Bio-Compatibility and Bio-Insulation of Implantable Electrode Prosthesis Ameliorated by A-174 Silane Primed Parylene-C Deposited Embedment.
Journal: Micromachines
Published: October 30, 2020
A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: May 08, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026